Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Figure 4

Recurrence-free survival in ER-positive patients with different genotypes of CYP2D6 and tamoxifen randomisation. The solid line represents patients homozygous for the CYP2D6*1 allele, and the dotted line represents patients homozygous or heterozygous for the CYP2D6*4 allele. (a) CYP2D6 and 2 years of tamoxifen therapy; (b) CYP2D6 and 5 years of tamoxifen therapy.

Back to article page